Dr. Beryl McCormick, MD

Dr. McCormick practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. McCormick's NPI, 1598745168, was assigned on January 19, 2006. Dr. McCormick graduated from Rutgers New Jersey Medical School in 1973. Dr. McCormick holds New York license 122873.

Dr. McCormick's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. McCormick's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Monmouth. Dmand AI also links Dr. McCormick to 4 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McCormick practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. McCormick's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. McCormick is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. McCormick's licenses on file in 4 states: New York, California, Florida and New Jersey.

Dmand AI lists breast cancer radiation among the conditions Dr. McCormick treats.

CMS data shows 1,025 Medicare services from Dr. McCormick across 11 procedure codes in 2024, for 269 Medicare patients. Medicare paid $69,601 for them.

CMS counts 269 Medicare patients who saw Dr. McCormick in 2024. The largest group is 65 to 74, with 143 patients. 75% of them have cancer, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McCormick's median patient age at 69, with 99% women.

In 2024, Dr. McCormick wrote 83 Medicare Part D claims for 52 patients. 86% of them were for generic drugs. CMS names the drug for 68 of them, across 1 drug with 11 or more claims each, at $583 in total drug cost. In 2023, CMS named 37 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. McCormick for performance year 2024, reported as part of a group. Dr. McCormick accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McCormick as offering telehealth.

Dmand AI links 171 papers to Dr. McCormick, published from 2002 to 2025. 2019 was the busiest year, with 9. The most frequent topics are Breast Neoplasms, Mastectomy, Segmental and Radiotherapy, Adjuvant. Dr. McCormick has published most often in Int J Radiat Oncol Biol Phys. Dr. McCormick's most frequent co-authors are Simon Nicholas Powell, MD, PhD, Lior Z. Braunstein, MD and Atif J. Khan, MD.

Dmand AI links Dr. McCormick to 5 clinical trials. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating and Breast Carcinoma In Situ. Memorial Sloan Kettering Cancer Center sponsors the most, 2.

CMS Open Payments shows 2 general payments to Dr. McCormick from 2 drug and device companies from 2017 to 2021. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $125.

Dmand AI lists 6 awards for Dr. McCormick, most recently America's Top Doctors in 2014.

Dr. McCormick graduated from Rutgers New Jersey Medical School in 1973. Dr. McCormick is a member of ASTRO and ASCO.

Dr. McCormick is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.